Scientific Presentations - Trovagene

Scientific Presentations

A Phase 2 Study of the Combination of PLK1 inhibitor, Onvansertib, with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

David J. Einstein, Atish Choudhury, Philip Saylor, Lillian Werner, Peter Croucher, Maya Ridinger, Mark Erlander, Glenn Bubley

A Phase 2 Study of Onvansertib (PCM-075) in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer

David J. Einstein, Atish Choudhury, Philip Saylor, Lillian Werner, Peter Croucher, Maya Ridinger, Mark Erlander, Glenn Bubley

Phase 1b Safety, Preliminary Anti-Leukemic Activity and Biomarker Analyses of the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Low-Dose Cytarabine or Decitabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Amer Zeidan, Alexander Spira, Pamela Becker, Prapti Patel, Gary Schiller, Michaela Tsai, Tara Lin, Eunice Wang, Maya Ridinger, Peter Croucher, Sandra Silberman, Mark Erlander, Jorge Cortes

A Phase 2 Study of Onvansertib (PCM-075) in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer

David J. Einstein, Atish Choudhury, Philip Saylor, Lillian Werner, Mark Erlander, Maya Ridinger, Glenn Bubley

Phase 1b Safety, Preliminary Anti-Leukemic Activity and Biomarker Analyses of the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Low-Dose Cytarabine or Decitabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Amer Zeidan, Alexander Spira, Pamela Becker, Prapti Patel, Gary Schiller, Michaela Tsai, Tara Lin, Maya Ridinger, Sandra Silberman, Mark Erlander, Jorge Cortes

Selective Polo-like Kinase 1 (PLK1) Inhibitor PCM-075 is Highly Active Alone and Shows Synergy When Combined with FLT3 Inhibitors in Models of Acute Myeloid Leukemia (AML)

Karena Kosco, Maya Ridinger, Penn Whitley, Antonella Ciavolella, Peter Croucher, Barbara Valsasina, Jeffrey N. Miner, Mark Erlander

Pharmacodynamic and Tumor Biomarker Analysis of a PLK1 Inhibitor, PCM-075, in a Phase 1b/2 Trial for Acute Myeloid Leukemia

Maya Ridinger, Karena Kosco, Latifa Hassaine, Shiloh Guerrero, Jeffrey N. Miner, Mark Erlander

Computationally Predicted Sensitivity of Clinical Cohorts Identifies Biomarkers Associated with Response to PCM-075, a PLK-1 Selective Inhibitor

Penn Whitley, Peter J P Croucher, Barbara Valsasina, Dario Ballinari, Italo Beria, Jeffrey N. Miner and Mark G. Erlander

Sensitivity of Triple Negative Breast Cancer Cell Lines to PCM-075, a Highly Selective Polo-like Kinase 1 Inhibitor

Jesse C. Patterson, Peter J P Croucher. Aleksandra Francovic, Dario Ballinari, Fabio Gasparri, Laura Giorgini, Penn Whitley, Barbara Valsasina, Marl Erlander and Michael B. Yafee